Loading stock data…
Soligenix (SNGX)
$0.40-0.01 (-2.44%)
After Hours$0.40-0.00 (-0.75%)· Last close Jun 29
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Soligenix, Inc. in the Healthcare sector is trading at $0.40 with a market capitalization of $6M. Wall Street consensus targets $1.75 (2 analysts), implying a +337.5% move over the next 12 months. The stock is currently near its 52-week low of $0.28, remaining 66.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +337.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$2.88M↑ | -$3.47M↓ | -$2.58M↑ | -$2.76M↑ | -$3.03M |
| Net Income | -$2.82M↑ | -$2.90M↓ | -$2.53M↑ | -$2.70M↑ | -$2.95M |
Peer Comparison
JNJUNHPFE
Fundamentals
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Healt...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.23M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-354.51%
Volume
Today's trading volume
404,959
Recent News
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy
Soligenix shares are also poised to break above the 100-day moving average for the first time in a month, following a four-session rally.
SNGX Phase 3 Trial Halted on HyBryte
The company’s FLASH2 study was stopped early after failing to show efficacy, shifting focus toward strategic alternatives and pipeline reassessment. Soligenix (SNGX) announced its Phase 3 trial halted for futility after an interim analysis of its FLASH2 study evaluating HyBryte™ in cutaneous T-cell lymphoma (CTCL), a development that may materially impact the drug’s regulatory path and the company’s near-term outlook.
Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky
NasdaqCM:SNGX 1 Year Share Price vs Fair Value Explore Soligenix's Fair Values from the Community and select yours Just...
BC-Most Active Stocks
Gibo Holdings Ltd. 62,368,609 0.0297
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial
Soligenix Inc. (NASDAQ:SNGX) shares surged on Thursday as the company announced positive results from its Phase 2a proof-of-concept study of SGX945 (dusquetide) in Behçet’s disease, a rare and chronic inflammatory condition. The session volume reached 28.71 million shares, significantly above the stock’s average daily volume of approximately 905,000, according to Benzinga Pro. The company reported that SGX945 achieved the trial’s primary goal of demonstrating biological efficacy in treating oral